HIP
TEVA icon

Hatteras Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Hatteras Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-29,598
Closed -$1.84M – 131
2015
Q1 		$1.84M Buy
+29,598
New +$1.72M 0.99% 34

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Hatteras Investment Partners's TEVA Position: Q2 2015 in Review

Hatteras Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 29,598 shares — an estimated $1.84M sold.

Hatteras Investment Partners first reported a position in TEVA in Q1 2015 and held it in 1 quarter. The position peaked at $1.84M in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • Hatteras Investment Partners reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Hatteras Investment Partners sold 29,598 Teva Pharmaceuticals shares in Q2 2015, an estimated $1.84M.
  • Hatteras Investment Partners first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's Teva Pharmaceuticals position peaked at $1.84M in Q1 2015.
  • 818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Hatteras Investment Partners's 13F filing for Q2 2015, filed 13 Aug 2015.